Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 16, 2014

N-of-One Tapped to Interpret OncoDNA's NGS Tests

N-of-One Tapped to Interpret OncoDNA's NGS Tests

Source: © uwimages - Fotolia.com

  • N-of-One inked an agreement with Belgian personalized medicine firm OncoDNA under which it will provide clinical interpretation for all of OncoDNA's next-generation sequencing (NGS) and other molecular tests for patients throughout Europe, the Middle East, and other parts of the world.

    OncoDNA provides tumor profiling services designed to help medical doctors choose treatments and monitor tumor evolution. N-of-One's clinical interpretation, OncoDNA says, can provide biological and clinical knowledge and insights related to a tumor's mutation profile, linking this knowledge to therapeutic strategies including clinical trials. In a statement, Jean-Pol Detiffe, OncoDNA's CEO, added that, in addition to clinical interpretation, N-of-One was tapped for its ability to integrate different types of molecular test results into a single report rapidly.

    "OncoDNA's industry-leading, molecular diagnostic solutions, coupled with N-of-One's deep expertise in clinical interpretation in oncology, will enable broader patient access worldwide to personalized cancer treatment in a scalable, cost-effective manner," commented N-of-One's CEO Chris Cournoyer.

    Back in March, N-of-One teamed up with genomics visualization and analysis software developer BioDiscovery to provide integrated genomic analysis interpretation solutions. It inked a similar deal with Appistry in February to provide genetic sequencing data analysis and molecular interpretation services.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »